Davoud Ahmadvand

An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome

Peter P. Wibroe, Davoud Ahmadvand, Mohammad Ali Oghabian et al. · Journal of Controlled Release · 2015 · 186 citations

Lipid Preparation, Drug Targeting, Integrated Assessment +3

Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead

S. Moein Moghimi, Alina J. Andersen, Sayed Hossein Hashemi et al. · Journal of Controlled Release · 2010 · 164 citations

Nanomedicine, Engineering, Complement Activation Cascade +9

Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide

Linping Wu, Davoud Ahmadvand, Junan Su et al. · Nature Communications · 2019 · 132 citations · Full text

T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy

Fatemeh Rahimi Jamnani, Fatemeh Rahbarizadeh, Mohammad Ali Shokrgozar et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2013 · 89 citations

Cell Therapy, Tumor Immunology, T Cells +6

Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents

Zahra Sharifzadeh, Fatemeh Rahbarizadeh, Mohammad Ali Shokrgozar et al. · Cancer Letters · 2012 · 74 citations

T Cells, Immunoengineering, Immunology +8